GAITHERSBURG, Md., Nov. 2, 2023
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global
company advancing protein-based vaccines with its Matrix-M™
adjuvant, today announced it will report its third quarter 2023
financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on
Thursday, November 9, 2023. Details
of the event and replay are as follows:
|
Conference call
details:
|
|
|
Date:
|
November 9,
2023
|
|
Time:
|
8:30 a.m. U.S.
EST
|
|
Dial-in number:
|
(877) 550-1858
(Domestic) or (848) 488-9160 (International)
|
|
Passcode:
|
1754341
|
|
Webcast:
|
ir.novavax.com/events
|
- Participants will be prompted to request to join the
Novavax, Inc. call.
- To ensure a timely connection, it is recommended that
participants join at least 10 minutes prior to the scheduled
webcast.
|
Replay
details:
|
|
|
Date:
|
Available starting at
11:30 a.m. EST, November 9, 2023, until
11:59 p.m. U.S. EST, November 16, 2023
|
|
Dial-in number:
|
(800) 645-7964
(Domestic) or (757) 849-6722 (International)
|
|
Passcode:
|
5567#
|
|
Webcast:
|
ir.novavax.com/events,
until February 7, 2024
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX)
promotes improved health by discovering, developing and
commercializing innovative vaccines to help protect against serious
infectious diseases. Novavax, a global company based in
Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. Focused on the
world's most urgent health challenges, Novavax is currently
evaluating vaccines for COVID-19, influenza and COVID-19 and
influenza combined. Please visit novavax.com and LinkedIn for
more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-third-quarter-2023-financial-results-and-operational-highlights-on-november-9-2023-301974716.html
SOURCE NOVAVAX, INC